NorthWest Biotherapeutics Inc (NWBO)

[br8k0ut]

Doesn't seem like failure to me



NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference in London



The top 20% of these patients have so far exceeded 2 years of survival and are still alive. The longest survivor to date has reached nearly 3 years. See Attachment A for details.

The top 30% of these patients (including pancreatic, melanoma, lung, ovarian, sarcoma and other cancers) as a combined group have an average survival to date of 26.7 months, compared with an average of expected survival times of 12.3 months. Individually, these patients have also substantially exceeded their respective expected survival times.  See Attachment B for details.

The continuing positive survival results correlate with underlying mechanisms of action and cellular and immune profiles, including phenotype analyses, relative production of a wide range of diverse cytokines by the dendritic cells. Additional positive observations include T-cell infiltration, and PD-L1 expression.

64% of the patients evaluable for PD-L1 checkpoint expression (14 of 22) showed either de novo or significantly increased expression of PD-L1 following DCVax-Direct treatment, indicating potential for combination of DCVax-Direct and checkpoint inhibitors.

The diverse cancers covered in this trial are responsible for approximately 800,000 new cases annually in the US and also at least 800,000 new cases in Europe. When these cancers reach the inoperable metastatic stage, there are no effective treatments available today.